PubMed Health⌕ Search

Biomedical subjects

M Hecker

Publications and source records attributed to M Hecker.

At least 181 records · Page 10Linked to original sources
PubMed1992

Comparison of the release of vasoactive factors from venous and arterial bovine cultured endothelial cells.

The release of endothelium-derived relaxing factor (EDRF), prostacyclin (PGI2), and endothelin-1 (ET-1) was measured from endothelial cells (EC) cultured from either bovine vena cava (BVCEC) or bovine aorta (BAEC). EDRF release was determined by using the superfusion bioassay technique, whereas ET-1 and PGI2 were measured by specific radioimmunoassays. Bradykinin (BK) (0.05-30 pmol) given through columns of venous or arterial EC induced a dose-dependent release of EDRF. BK (0.05 pmol) evoked a release of EDRF from venous EC that was similar to the effect of a dose of 1 pmol from arterial EC. As with BAEC, infusions of NG-monomethyl-L-arginine (30 microM) caused an inhibition of EDRF release from BVCEC that was partially reversed by coinfusions of L-arginine (L-Arg; 100 microM). BK also induced a dose-dependent release of PGI2 from BVCEC. BVCEC and BAEC produced PGI2 in equivalent amounts when arachidonic acid (9.2 and 32 pmol) was added to the Krebs' solution perfusing the cells. BVCEC and BAEC released detectable amounts of ET-1 (0.4 +/- 0.1 and 0.9 +/- 0.3 ng/mL, respectively), over a 4-h period, and the release of ET-1 was increased approximately twofold by coincubations with thrombin (0.05-1 U/mL). These findings demonstrate that venous EC have a similar capacity to arterial EC to release vasoactive factors, thus supporting the hypothesis that veins have a functional endothelium that may modulate venous tone and platelet function.

Amino Acids↗
PubMed1992

Role of intracellular thiols in release of EDRF from cultured endothelial cells.

The availability of intracellular reduced thiols, such as L-cysteine or glutathione (GSH), may be critically important for the biosynthesis of endothelium-derived relaxing factor (EDRF). We have, therefore, investigated the effects of various sulfhydryl (SH) reagents, such as 1-chloro-2,4-dinitrobenzene (CDNB), diamide, 2,2'-dithiodipyridine (DTDP), or N-ethyl-maleimide (NEM), on the release of EDRF from cultured endothelial cells. None of the SH reagents tested affected the flow-induced EDRF release, but DTDP and NEM inhibited the release of EDRF stimulated by ADP, ionomycin, or poly-L-lysine. In contrast, NG-nitro-L-arginine methyl ester, an inhibitor of EDRF biosynthesis, blocked both the flow- and agonist-induced release of EDRF. Although NEM substantially potentiated the flow-induced release of prostacyclin (PGI2), probably due to a blockade of the reacylation of arachidonic acid, it inhibited the stimulated release of PGI2, whereas diamide did not significantly affect either release. Like CDNB or diamide, NEM, but not DTDP, caused a significant decrease in endothelial GSH. In contrast, both NEM and DTDP, but not CDNB or diamide, inhibited the ADP-induced mobilization of intracellular calcium, suggesting that they act on specific target proteins involved in endothelial cell calcium homeostasis rather than intracellular free SH groups. Moreover, the selective inhibition by these two SH reagents of the stimulated release of EDRF implies that a fundamental regulatory difference exists between agonist- and flow-induced EDRF biosynthesis.

Adenosine Diphosphate↗
PubMed1992

Stimulation of endothelial autacoid formation by inhibitors of angiotensin-converting enzyme.

We have investigated in human endothelial cells in culture the effects of angiotensin-converting enzyme (ACE) inhibitors on the concentration of intracellular free Ca2+ ([Ca2+]i) and the formation of nitric oxide (NO) and prostacyclin (PGI2). Enalaprilat, moexiprilat and ramiprilat similarly potentiated the increase in [Ca2+]i elicited by bradykinin and caused an increase in resting [Ca2+]i when given alone. The latter effect was long-lasting and accompanied by an increased formation of NO and PGI2. All of these effects were inhibited by the B2-kinin receptor antagonist Hoe 140, suggesting that the endogenous synthesis/release of bradykinin represents an autocrine mechanism for the stimulation of endothelial autacoid formation. Thus these findings strongly support the concept that ACE inhibitors promote local vasodilation by increasing the level of bradykinin generated in subthreshold concentrations by the endothelium.

1-Methyl-3-isobutylxanthine↗
PubMed1992

Role of endothelium-derived bradykinin in the control of vascular tone.

We have investigated the effects of angiotensin-converting enzyme (ACE) inhibitors on intracellular Ca2+ levels in human cultured endothelial cells and on endothelial autacoid formation in endothelium-intact bovine coronary arteries and in isolated perfused rabbit and rat hearts. Incubation of cultured endothelial cells with ramiprilat (0.3 microM) caused a maintained increase in resting intracellular Ca2+. This effect was long-lasting, accompanied by an increased formation of both nitric oxide (NO) and prostacyclin (PGI2), and was abolished by the specific B2-kinin receptor antagonist Hoe 140. Ramiprilat also significantly enhanced the increase in intracellular Ca2+ elicited by bradykinin (3 nM). In endothelium-intact bovine coronary arteries, moexiprilat (0.3 microM), like bradykinin (30 nM), caused a nearly twofold increase in the vascular cGMP content which was abolished by both NG-nitro-L-arginine (30 microM) and removal of the endothelium. The functional consequences of this ACE inhibitor-induced increase in vascular cGMP content were reflected by a distinct relaxation of the coronary segments preconstricted with prostaglandin F2 alpha. In the isolated perfused rabbit heart, ramiprilat (0.3 microM) affected neither resting vascular tone nor endothelial autacoid release; however, the vasodilation and release of PGI2 in response to exogenously applied bradykinin (10 nM) were significantly enhanced by ramiprilat. This effect was also seen using moexiprilat (0.1 microM) in the isolated perfused rat heart. Although these findings suggest that endothelium-derived bradykinin is not involved in the control of resting vascular tone in the coronary microcirculation of the rabbit and the rat, there appears to be significant ACE activity to modulate bradykinin-induced endothelial autacoid formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1991

Nitric oxide and another potent vasodilator are formed from NG-hydroxy-L-arginine by cultured endothelial cells.

The hypothesis was investigated that NG-hydroxy-L-arginine (L-HOArg) is an intermediate in the biosynthesis of nitric oxide (.NO) from L-arginine (L-Arg) by the constitutive .NO synthase (NOS) present in endothelial cells (ECs). When infused through a column of bovine aortic ECs on beads, either L-HOArg or D-HOArg (1-10 microM) substantially potentiated relaxations of the bioassay tissues to .NO released from the cells by ADP or bradykinin, and this effect was abolished by coinfusions of NG-nitro-L-arginine (L-NO2Arg) methyl ester (10 microM) or NG-monomethyl-L-arginine (L-MeArg; 30 microM). Both L-HOArg and D-HOArg, irrespective of the presence of ECs, also potentiated relaxations induced by authentic .NO, but not glyceryl trinitrate. This was due to a rapid chemical reaction of either isomer with .NO, resulting in the formation of a potent and more stable vasodilator. When infusions of L-HOArg (3 microM) were consequently made in the presence of D-HOArg (10 microM), the L-isomer no longer had any effect on relaxations induced by authentic .NO, but significantly increased the stimulated release of .NO from the column of ECs. The conclusion that L-HOArg is a substrate for the constitutive NOS in cultured ECs was strongly supported by the L-NO2Arg-sensitive conversion of L-HOArg, but not D-HOArg, to .NO by NOS preparations from these cells. Interestingly, cultured ECs produced from L-HOArg (greater than or equal to 3 microM), but not D-HOArg, a stable vasodilator, the effects of which were inhibited by oxyhemoglobin (0.3-3 microM). However, the formation of this substance was not prevented by L-NO2Arg methyl ester (10 microM) or L-MeArg (10-100 microM), suggesting an enzymatic pathway different from NOS.

Animals↗
PubMed1991

On the substrate specificity of nitric oxide synthase.

Nitric oxide (.NO) synthase (NOS) activity in subcellular fractions from cultured endothelial cells (EC) and lipopolysaccharide-activated J774.2 monocyte/macrophages was investigated by monitoring the .NO-mediated increase in intracellular cyclic GMP in LLC-PK1 pig kidney epithelial cells. The constitutive NOS in EC (NOSc) was largely membrane-bound, whereas the inducible NOS in J774.2 cells (NOSi) was equally distributed among cytosol and membrane(s). Both the cytosolic NOSc in EC and the membrane-bound NOSi in J774.2 cells were strictly Ca(2+)-dependent, whereas the membrane-bound NOSc in EC and the cytosolic NOSi in J774.2 cells were not. L-Homoarginine and L-arginine-containing small peptides, such as L-arginyl-L-phenylalanine, replaced L-arginine as a substrate for the NOSc in EC and the Ca(2+)-independent NOSi in J774.2 cells, but not the Ca(2+)-dependent NOSi. Thus, irrespective of their intracellular localisation, at least three isoforms of NOS exist, which can be differentiated by their substrate specificity and Ca(2+)-dependency.

Amino Acid Oxidoreductases↗
PubMed1991

Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP.

The osteoclast is unique in its ability to resorb bone, and excessive osteoclastic activity has been implicated in osteoporosis, Paget disease of bone, rheumatoid arthritis, and the growth of metastases in bone. The activity of this cell is controlled by the main circulating inhibitor, calcitonin, in association with locally produced modulators. We show that nitric oxide (NO) may be an important member of the latter group. NO is produced by the vascular endothelium and nervous system and is involved in both neurotransmission and the regulation of blood pressure. However, our results show that the autocoid is also a potent inhibitor of osteoclast function. NO (30 microM) produced a decrease to approximately 50% of the original osteoclast spread area. Similar effects were also produced by 3-morpholinosydnonimine or sodium nitroprusside, reagents that spontaneously release NO. These shape changes were associated with a reduction of bone resorption after a 24-hr incubation of isolated osteoclasts on devitalized bone slices. NO is thought to act by stimulating guanylate cyclase, with a consequent increase in cyclic GMP, but a different mode of action is likely in the osteoclast since dibutyryl or 8-bromo cyclic GMP have no effect. It should be noted that calcitonin can produce similar changes in shape and activity but is associated with an increase in osteoclast intracellular calcium and cessation of membrane movement; neither of these is produced by NO, suggesting that its mode of action is different. The abundance of NO-producing endothelial cells in bone marrow and their proximity to osteoclasts suggests that marrow endothelial cells may play a physiological role in the regulation of osteoclastic activity.

Animals↗
PubMed1991

FMRF-amide and L-Arg-L-Phe increase blood pressure and heart rate in the anaesthetised rat by central stimulation of the sympathetic nervous system.

The neuropeptide FMRFamide (L-Phe-L-Met-L-Arg-L-Phe-NH2) increases mean arterial blood pressure (MABP) and heart rate (HR) in the anaesthetised rat at concentrations ranging from 10-1000 micrograms/kg. Here, we demonstrate that peptides containing L-arginyl-L-phenylalanine (L-Arg-L-Phe), the C-terminal sequence of FMRFamide, mimic its haemodynamic effects. L-Arg-L-Phe was approximately 4 fold more potent in increasing MABP and HR than FMRFamide. In 40 different peptides investigated, the following order of potency of the effective compounds was established: L-Arg-L-Phe-L-Ala = L-Arg-L-Phe greater than FMRFamide greater than L-Met-L-Arg-L-Phe = L-Arg-L-Trp greater than L-Arg-L-Tyr greater than D-Arg-L-Phe = L-Arg-L-Phe-OMe greater than L-Arg-L-Leu = L-Arg-L-Ile greater than L-Lys-L-Phe greater than L-Arg-L-Met. L-Arg-L-Phe or FMRFamide did not cause any pressor response in pithed rats, indicating a central mechanism of action. In anaesthetised rats, intravenous injections of FMRFamide or L-Arg-L-Phe (100 micrograms/kg) were associated with a 2-3 fold increase in plasma noradrenaline levels, whereas plasma adrenaline levels remained unchanged. Thus, L-Arg-L-Phe may represent the active principle of FMRFamide acting by a central mechanism involving the release of noradrenaline from sympathetic nerve terminals.

Amino Acid Sequence↗
PubMed1991

The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes.

Human polymorphonuclear leukocytes (PMNs) converted human big endothelin (bET; 2 microM) to an endothelin-1 (ET-1) like contractile factor, as assessed by bioassay. The generation of this ET-1 like activity was rapid (minutes), time-dependent and more pronounced in non-activated cells, suggesting a partial degradation by activated PMNs. Phosphoramidon (54 micrograms/ml) inhibited the formation of this contractile factor, whereas phenylmethylsulfonylfluoride (PMSF; 25 micrograms/ml), pepstatin A (1 microgram/ml) or epoxysuccinyl-L-leucylamido-(guanidino)butane (E-64; 10 micrograms/ml) did not. Incubations of activated PMNs with PMSF significantly potentiated the generation of ET-1 like activity and selectively inhibited the degradation of [125I]ET-1 by activated PMNs. These findings indicate that human PMNs contain and/or release neutral proteases, which can both rapidly produce and degrade ET-1, an observation which may have important (patho)physiologic implications.

Animals↗
PubMed1991

Stringent control of replication of plasmids derived from coliphage lambda.

The first events of lambda plasmid replication in vivo, which probably regulate this process, are the transcriptional activation of the origin of replication by RNA polymerase and the binding of the initiator protein, lambda O, to this nucleotide sequence. The lambda O protein is known for its rapid proteolytic degradation; hence amino acid starvation of Escherichia coli should result in inhibition of lambda plasmid replication caused by inhibition of protein synthesis. However, contrary to this prediction, we found that lambda plasmid replication, as measured by the increase in plasmid content per bacterial mass, proceeds for hours in an amino acid-starved, relaxed mutant, whereas it is inhibited in its wild-type stringent partner. lambda plasmid replication in amino acid-starved, relaxed cells reveals absolute lambda O dependence and is not inhibited by chloramphenicol at 200 micrograms/ml. This process also occurs in wild-type cells treated with chloramphenicol. We conclude that lambda plasmid replication is under stringent control, probably as a result of the action of ppGpp, the indirect product of the relA gene, on RNA polymerase. The problem of stability of the lambda O initiator protein is discussed.

Bacteriophage lambda↗
PubMed1991

Human polymorphonuclear leukocytes generate and degrade endothelin-1 by two distinct neutral proteases.

Human polymorphonuclear leukocytes (PMNs, 4 x 10(6)/ml) converted human big endothelin (bET) to an endothelin-1 (ET-1)-like contractile factor, as assessed by bioassay. The formation of this ET-1-like activity from bET was partially inhibited by phosphoramidon (54 micrograms/ml), but not by pepstatin-A (1 microgram/ml), epoxysuccinyl-L-leucylamido(guanidino)butane (E-64, 10 micrograms/ml) or phenylmethylsulfonyl fluoride (PMSF, 25 micrograms/ml). In addition, nonactivated PMNs converted [125I]bET to [125I]ET-1, thus confirming the bioassay results. Incubation of ET-1 with fMLP-activated PMNs or cell-free supernatants from activated PMNs resulted in the loss of its contractile activity, and this loss of activity was paralleled by the metabolism of [125I]ET-1. The metabolism of [125I]ET-1 by PMNs or leukocyte cathepsin G (5 micrograms/ml) was prevented by PMSF (25 micrograms/ml), but not by phosphoramidon (54 micrograms/ml) or pepstatin-A (1 microgram/ml). Thus, PMNs can form ET-1 from bET via a neutral protease and degrade ET-1 via a serine protease, an observation that may have important pathophysiologic implications in disease states associated with PMN infiltration.

Animals↗
PubMed1991

Inhibition of the release of endothelium-derived relaxing factor in vitro and in vivo by dipeptides containing NG-nitro-L-arginine.

1. We have shown that dipeptides containing NG-nitro-L-arginine (NO2Arg) inhibit the biosynthesis of endothelium-derived relaxing factor (EDRF) in vitro and in vivo. 2. In anaesthetized rats, intravenous administration at 1-30 mg kg-1 of the methyl ester of NO2Arg, NO2-Arg-L-phenylalanine (NO2Arg-Phe), L-alanyl-NO2Arg (Ala-NO2Arg) or NO2Arg-L-arginine (NO2Arg-Arg) produced dose-related increases in mean arterial blood pressure (MABP) which were unaffected by D-arginine (D-Arg; 20 mg kg-1 min-1 for 15 min), but prevented by co-infusions of L-arginine (L-Arg; 20 mg kg-1 min-1 for 15 min) or by their parent dipeptides. 3. NO2Arg methyl ester, NO2Arg-Phe methyl ester or Ala-NO2Arg methyl ester (10 mg kg-1, i.v.) also inhibited the reduction in MABP caused by the endothelium-dependent vasodilator, acetylcholine (30 micrograms kg-1 min-1 for 3 min), but not those induced by glycerly trinitrate (20 micrograms kg-1 min-1 for 3 min) or iloprost (6 micrograms kg-1 min-1 for 3 min) which act directly on the vascular smooth muscle. 4. Moreover, NO2Arg methyl ester, NO2Arg-Phe methyl ester or NO2Arg-Arg methyl ester (100 microM) inhibited the acetylcholine-induced relaxation of rabbit aortic strips, and NO2Arg-Phe methyl ester (30 microM) blocked the stimulated (bradykinin, 30 pmol) release of EDRF from bovine aortic endothelial cells grown on microcarrier beads. 5. In endothelial cells grown in L-Arg-deficient medium, L-Arg-containing dipeptides such as L-Arg-LPhe, L-Ala-L-Arg or L-Arg-L-Arg increased both the basal and stimulated release of EDRF. Moreover, the L-Arg containing dipeptides, but not their NO2Arg analogues, were rapidly cleaved by these cells. 6. Thus, dipeptides containing NO2Arg can directly interfere with the biosynthesis of EDRF in vitro and in vivo. Moreover, the potentiation of EDRF release from endothelial cells deprived of L-Arg by dipeptides containing L-Arg suggests that such peptides may serve as an additional or alternative substrate for the biosynthesis of EDRF.

Amino Acid Sequence↗
PubMed1990

L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta.

The present study investigates the effect of the amino acid L-glutamine (L-Gln) on the release of endothelium-derived relaxing factor (EDRF) from the luminally perfused rabbit aorta and on endothelium-dependent relaxations of rabbit aortic strips. L-Gln (200 microM) had no effect on the acetylcholine (Ach)-induced release of EDRF from freshly prepared aortic tissues. The concentration of L-arginine (L-Arg) in endothelial cells isolated from these aortae was approximately 4 mM, as determined by HPLC analysis. After an initial equilibration period of 2 h and two consecutive infusions of Ach (55 microM for 15 min) at 2 and 3 h, L-Arg levels fell by 62 +/- 14% (n = 4). Under these conditions, L-Gln (200 microM) but not D-Gln (200 microM) inhibited the release of EDRF by 50 +/- 4% (n = 7). This effect of L-Gln was partially reversed by infusions of L-Arg (500 microM) but not D-Arg (500 microM). L-Gln (200 microM) but not D-Gln (200 microM) potentiated the inhibitory effect of N omega-nitro-L-arginine (30 microM), an inhibitor of EDRF biosynthesis, on Ach-induced relaxations of rabbit aortic strips, whereas L-Gln alone had no effect. Thus, L-Gln inhibits the release of EDRF from intact blood vessels presumably by interfering with the generation of L-Arg by the endothelium.

Acetylcholine↗
PubMed1990

Cultured endothelial cells maintain their L-arginine level despite the continuous release of EDRF.

Endothelial cells cultured from bovine aorta and grown on microcarrier beads contain 107 +/- 9 microM L-arginine (Arg; n = 11). When packed into a jacketed chromatography column and perfused with Krebs solution, the cells showed a substantial and sustained release of endothelium-derived relaxing factor (EDRF) for up to 2 h, which was further enhanced by infusions of adenosine diphosphate (4 microM). In contrast to other amino acids, such as L-alanine, L-aspartate, L-glutamine, L-glutamate or L-serine, which showed a time-dependent decrease to less than 30% of their original level within 2 h, Arg remained at control levels for 30 min and decreased only by 25% after 2 h. Thus endothelial cells can generate Arg from an intracellular source to maintain their Arg level despite the continuous formation of EDRF.

Amino Acids↗
PubMed1990

Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine.

NG-monomethyl-L-arginine (MeArg) inhibits the release of endothelium-derived relaxing factor (EDRF) from endothelial cells (EC) and the formation of nitric oxide (NO) from L-arginine (Arg) in EC and activated macrophages. We have compared the inhibitory potency of MeArg to that of N omega-nitro-L-arginine (NO2Arg), a more potent inhibitor of EDRF synthesis in vitro. NO2Arg (100 microM) was significantly more potent than MeArg in inhibiting the endothelium-dependent relaxation of rabbit aorta induced by acetylcholine. MeArg and NO2Arg (10 and 30 microM) also inhibited the release of EDRF from bovine aortic cultured EC. In the anaesthetized rat in vivo, the pressor effect of NO2Arg (3 and 10 mg kg-1) was significantly larger and longer lasting than that of MeArg. These differences in potency could be due to the extensive metabolism of MeArg but not NO2Arg to L-citrulline (Cit) and subsequently to Arg by EC. The enzyme responsible for the conversion of MeArg to Cit had the characteristics of a novel deiminase, NG,NG-dimethylarginine dimethylaminohydrolase, recently isolated from rat kidney.

Acetylcholine↗
PubMed1990

Amplification of pBR322 plasmid DNA in Escherichia coli relA strains during batch and fed-batch fermentation.

Fermenter studies under batch and fed-batch conditions were carried out to test the possibility of plasmid pBR322 production in large amounts by using E. coli relA strains. High amplification rates of pBR322 plasmid DNA were observed in E. coli CP79 (relA) and E. coli CP143 (relA) in both batch and fed-batch cultivation after exhaustion of the amino acid arginine. The concentrations of plasmid DNA per unit of biomass were nearly the same in batch and in fed-batch fermentations of E. coli CP79 and E. coli CP143. Therefore, the significantly higher biomass concentration of the two strains after fed-batch fermentation gave a dramatic increase in the yield of plasmid DNA per litre of medium in comparison to the batch process. The results support the suggestion that E. coli relA strains are suitable hosts for production of large amounts of ColE1-derived plasmids for recombinant DNA research.

DNA, Bacterial↗
PubMed1990

Selection, training, and quality control of Type A interviewers in a prospective study of young adults.

This paper describes Type A/B interviewer selection, training, and quality control results in a prospective study of coronary artery risk development in young adults (CARDIA). Interviewer behaviors from 152 CARDIA structured interviews were audited and compared with 747 Western Collaborative Group Study (WCGS) interviews and 577 Multiple Risk Factor Intervention Trial (MRFIT) interviews. The results show success in modeling the CARDIA interviewer behaviors on those of the WCGS. CARDIA interviews were very similar to WCGS interviews for interview length, number of questions asked, and speed of speaking; they were similar to MRFIT interviews in latency of asking questions. CARDIA interviewer behaviors remained fairly consistent over the four time periods. Comparing the clinics, there were regional differences in latency of asking and speed of speaking, with the Southern clinic having a longer asking latency and speaking more slowly. There were differences between individual interviewers in most characteristics, particularly those that were more free to vary. The study provides procedures and guidelines designed to maintain quality control of the structured interview process.

Adolescent↗